-
![HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS](/abs-image/US/2014/06/12/US20140163015A1/abs.jpg.150x150.jpg)
公开(公告)号：US20140163015A1
公开(公告)日：2014-06-12
申请号：US14101462
申请日：2013-12-10
Applicant: Pfizer Inc.
Inventor： Michael Aaron Brodney , Elizabeth Mary Beck , Christopher Ryan Butler , Jennifer Elizabeth Davoren , Brian Thomas O'Neill
IPC: C07D513/04
CPC classification number: A61K31/542 , C07D513/04
Abstract: The present invention provides compounds of Formula I, and the tautomers thereof, and the pharmaceutically acceptable salts of the compounds and tautomers, wherein the compounds have the structure wherein the variables R1, R2, R3, R4 and x are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
Abstract translation: 本发明提供式I化合物及其互变异构体，以及化合物和互变异构体的药学上可接受的盐，其中化合物具有其中变量R1，R2，R3，R4和x如说明书中所定义的结构。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。
-
公开(公告)号：US20230192690A1
公开(公告)日：2023-06-22
申请号：US18112156
申请日：2023-02-21
Applicant: PFIZER INC.
Inventor： Lei Zhang , Christopher Ryan Butler , Elizabeth Mary Beck , Michael Aaron Brodney , Matthew Frank Brown , Laura Ann McAllister , Erik Alphie LaChapelle , Adam Matthew Gilbert
IPC: C07D471/04 , A61P25/00 , A61P25/16 , A61P25/18 , A61P25/28 , A61K31/437
CPC classification number: C07D471/04 , A61P25/00 , A61P25/16 , A61P25/18 , A61P25/28 , A61K31/437
Abstract: The present invention provides, in part, compounds of Formula I:
or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: R1, R2, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.-
公开(公告)号：US20200207762A1
公开(公告)日：2020-07-02
申请号：US16797966
申请日：2020-02-21
Applicant: Pfizer Inc.
Inventor： Lei Zhang , Christopher Ryan Butler , Elizabeth Mary Beck , Michael Aaron Brodney , Matthew Frank Brown , Laura Ann McAllister , Erik Alphie LaChapelle , Adam Matthew Gilbert
IPC: C07D471/04 , A61P25/28 , A61P25/18 , A61P25/16 , A61P25/00
Abstract: The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: R1, R2, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.
-
公开(公告)号：US10604519B2
公开(公告)日：2020-03-31
申请号：US15637071
申请日：2017-06-29
Applicant: Pfizer Inc.
Inventor： Lei Zhang , Christopher Ryan Butler , Elizabeth Mary Beck , Michael Aaron Brodney , Matthew Frank Brown , Laura Ann McAllister , Erik Alphie LaChapelle , Adam Matthew Gilbert
IPC: C07D471/04 , A61P25/00 , A61P25/16 , A61P25/18 , A61P25/28
Abstract: The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: R1, R2, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.
-
公开(公告)号：US10428034B2
公开(公告)日：2019-10-01
申请号：US15808242
申请日：2017-11-09
Applicant: PFIZER INC.
Inventor： Christopher Ryan Butler , Laura Ann McAllister , Elizabeth Mary Beck , Michael Aaron Brodney , Adam Matthew Gilbert , Christopher John Helal , Douglas Scott Johnson , Justin Ian Montgomery , Steven Victor O'Neil , Bruce Nelsen Rogers , Patrick Robert Verhoest , Damien Webb
IPC: C07D295/14 , C07D401/14 , C07D401/04 , C07D403/04 , C07D498/10 , C07D491/107 , C07D401/12 , C07D471/10 , C07D487/04 , C07D211/48 , C07D471/08 , C07D515/10 , C07F9/6561 , C07D405/14 , C07D413/14 , C07D405/12 , C07D493/10
Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.
-
Patent Agency Ranking
![2-Amino-6-Methyl-4,4a,5,6-Tetrahydropyrano[3,4-d][1,3]Thiazin-8a(8H)-yl-1,3-Thiazol-4-yl Amides](/abs-image/US/2017/06/01/US20170151252A1/abs.jpg.150x150.jpg)
36.发明申请公开(公告)号：US20170151252A1
公开(公告)日：2017-06-01
申请号：US15427350
申请日：2017-02-08
Applicant: Pfizer Inc.
Inventor： Michael Aaron Brodney , Elizabeth Mary Beck , Christopher Ryan Butler , Lei Zhang , Brian Thomas O'Neill , Gabriela Barreiro , Erik Alphie LaChapelle , Bruce Nelsen Rogers
IPC: A61K31/542
CPC classification number: A61K31/542 , C07D513/04 , C07D519/00
Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variable R1 is as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
![Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds](/abs-image/US/2016/02/16/US09260455B2/abs.jpg.150x150.jpg)
37.发明授权Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds 有权烷基取代的六氢吡喃并[3,4-d] [1,3]噻嗪-2-胺化合物公开(公告)号：US09260455B2
公开(公告)日：2016-02-16
申请号：US14429215
申请日：2013-09-09
Applicant: Pfizer Inc.
Inventor： Michael Aaron Brodney , Elizabeth Mary Beck , Christopher Ryan Butler , Jennifer Elizabeth Davoren
IPC: C07D513/04
CPC classification number: C07D513/04
Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I, wherein the variables R1 and R2 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
Abstract translation: 公开了化合物的化合物，互变异构体和药学上可接受的盐，其中化合物具有式I的结构，其中变量R1和R2如说明书中所定义。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。
-
![Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds](/abs-image/US/2015/08/20/US20150231144A1/abs.jpg.150x150.jpg)
公开(公告)号：US20150231144A1
公开(公告)日：2015-08-20
申请号：US14695920
申请日：2015-04-24
Applicant: Pfizer Inc.
Inventor： Michael Aaron Brodney , Elizabeth Mary Beck , Christopher Ryan Butler , Jennifer Elizabeth Davoren , Brian Thomas O'Neill
IPC: A61K31/542
CPC classification number: A61K31/542 , C07D513/04
Abstract: The present invention provides compounds of Formula I, and the tautomers thereof, and the pharmaceutically acceptable salts of the compounds and tautomers, wherein the compounds have the structure wherein the variables R1, R2, R3, R4 and x are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
Abstract translation: 本发明提供式I化合物及其互变异构体，以及化合物和互变异构体的药学上可接受的盐，其中化合物具有其中变量R1，R2，R3，R4和x如说明书中所定义的结构。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。
-
![Heterocyclic Substituted Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds](/abs-image/US/2015/05/14/US20150133438A1/abs.jpg.150x150.jpg)
39.发明申请Heterocyclic Substituted Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds 审中-公开杂环取代的六氢吡喃并[3,4-d] [1,3]噻嗪-2-胺化合物公开(公告)号：US20150133438A1
公开(公告)日：2015-05-14
申请号：US14593587
申请日：2015-01-09
Applicant: Pfizer Inc.
Inventor： Michael Aaron Brodney , Christopher Ryan Butler , Elizabeth Mary Beck , Jennifer Elizabeth Davoren , Brian Thomas O'Neill
IPC: C07D513/04
CPC classification number: C07D513/04 , A61K31/542
Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
Abstract translation: 公开了化合物的化合物，互变异构体和药学上可接受的盐，其中化合物具有如说明书中定义的式I的结构。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。
-
![Heterocyclic substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds](/abs-image/US/2015/02/24/US08962616B2/abs.jpg.150x150.jpg)
40.发明授权Heterocyclic substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds 有权杂环取代的六氢吡喃并[3,4-d] [1,3]噻嗪-2-胺化合物公开(公告)号：US08962616B2
公开(公告)日：2015-02-24
申请号：US13886405
申请日：2013-05-03
Applicant: Pfizer Inc.
Inventor： Michael Aaron Brodney , Christopher Ryan Butler , Elizabeth Mary Beck , Jennifer Elizabeth Davoren , Brian Thomas O'Neill
IPC: C07D498/04 , A61K31/541 , C07D513/04 , A61K31/542
CPC classification number: C07D513/04 , A61K31/542
Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I, as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
Abstract translation: 公开了化合物的化合物，互变异构体和药学上可接受的盐，其中化合物具有如说明书中定义的式I的结构。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。
-
-
-
-
-
-
-
-
-
Search Results
41
records
(took 0.035 seconds)
